Citi analyst David Hoang lowered the firm’s price target on Axsome Therapeutics to $125 from $127 and keeps a Buy rating on the shares following the Q1 report. Auvelity overcame seasonal headwinds to report $53.4M in revenue, a modest beat, with favorable script trends exiting the quarter and progress on payor contracting that may lead to better formulary coverage near-term, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- AXSM Earnings this Week: How Will it Perform?
- Axsome Therapeutics recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue